Astrana Health, Inc.
NASDAQ:ASTHMedical - Care Facilities
+$1.03 today
- Market cap
- $1.47B
- Beta
- 0.94
- P/E (TTM)
- 63.3
- EPS (TTM)
- $0.62
Volume 0.52M
Average 0.51M
ASTH Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Astrana Health, Inc.NASDAQ: ASTH
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows, but more slowly than its trailing trend
Q1 FY2026 cost of revenue of $874.84M rose 59.3% year over year, behind the +61.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +45.1% a year.
Context
- Cost of revenue amounted to 90.7% of revenue in FY2025, up 4.0 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +59.3% toward the trailing-twelve-month pace of +61.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 2.89B USD
- Year-over-year change
- +63.7%
- 4-year CAGR
- +48.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.89B | +63.7% |
| FY2024 | 2024-12-31 | 1.76B | +50.5% |
| FY2023 | 2023-12-31 | 1.17B | +24.0% |
| FY2022 | 2022-12-31 | 944.69M | +58.5% |
| FY2021 | 2021-12-31 | 596.14M | — |
Cost of Revenue vs competitors
How ASTH compares with its peers on the latest reported figures
- ASTH's LTM Mar 2026 cost of revenue of $3.2B is the 2nd highest of the 4 companies compared; the peer median is $2.18B.
- Its year-over-year change of +61.8% is the highest of 4, against a peer median of +27.2%.
- Cost of revenue amounts to 90.7% of revenue for ASTH, versus a peer median of 92.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.98B | -0.5% | +39.0% | 102.7% | |
| LTM Mar 2026 | $3.2B | +61.8% | +45.1% | 90.7% | |
| LTM Jun 2026 | $2.18B | +27.2% | +16.1% | 92.4% | |
| LTM Mar 2026 | $462.28M | +44.5% | +28.3% | 52.5% | |
| Peer median (excluding ASTH) | $2.18B | +27.2% | +28.3% | 92.4% | |
Competitors are the stored peer set for ASTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 773.92M | 1.14B | 1.39B | 2.03B | 3.18B |
| Cost of Revenue | 596.14M | 944.69M | 1.17B | 1.76B | 2.89B |
| Gross Profit | 177.77M | 199.48M | 214.96M | 271.39M | 295.78M |
| Gross Margin | 23.0% | 17.4% | 15.5% | 13.3% | 9.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 62.08M | 77.67M | 112.6M | 154.11M | 217.26M |
| Operating Expenses | 79.59M | 95.21M | 130.35M | 182.04M | 217.26M |
| Depreciation & Amortization | 17.52M | 17.54M | 17.75M | 27.93M | 45.75M |
| EBITDA | 100.66M | 112.08M | 123.69M | 141.84M | 135.28M |
| EBITDA Margin | 13.0% | 9.8% | 8.9% | 7.0% | 4.3% |
| Operating Income | 98.18M | 104.27M | 84.61M | 89.35M | 78.53M |
| Operating Margin | 12.7% | 9.1% | 6.1% | 4.4% | 2.5% |
| Interest Income | 1.57M | 1.98M | 14.21M | 14.51M | 12.16M |
| Interest Expense | 5.39M | 7.92M | 16.1M | 33.1M | 49.93M |
| Other Income / Expenses | (20.43M) | (17.65M) | 5.23M | (8.53M) | (38.92M) |
| Income Before Tax | 77.75M | 86.62M | 89.84M | 80.82M | 39.61M |
| Pre-Tax Margin | 10.0% | 7.6% | 6.5% | 4.0% | 1.2% |
| Income Tax Expense | 31.69M | 40.88M | 31.99M | 30.89M | 15.53M |
| Net Income | 68.92M | 45.17M | 60.72M | 43.15M | 22.49M |
| Net Margin | 8.9% | 3.9% | 4.4% | 2.1% | 0.7% |
| EPS (Basic) | 1.57 | 1.00 | 1.30 | 0.91 | 0.46 |
| EPS (Diluted) | 1.52 | 0.99 | 1.29 | 0.90 | 0.46 |
| Weighted Avg Shares | 43.83M | 44.97M | 46.71M | 47.69M | 49.08M |
| Weighted Avg Shares (Diluted) | 45.4M | 45.6M | 47.07M | 48.22M | 49.37M |
Astrana Health, Inc.
NASDAQ:ASTH
Intrinsic Alpha fair value
Locked
Current Price
$29.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.